BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 14992195)

  • 1. [Stem cells in hematology and oncology].
    Goldschmidt H; Egerer G; Fruehauf S; Ho AD
    Med Klin (Munich); 2003 Dec; 98 Suppl 2():11-4. PubMed ID: 14992195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival.
    Dean R; Masci P; Pohlman B; Andresen S; Serafino S; Sobecks R; Kuczkowski E; Curtis J; Maciejewski J; Rybicki L; Kalaycio M; Hsi E; Theil K; Bolwell BJ
    Bone Marrow Transplant; 2005 Dec; 36(12):1049-52. PubMed ID: 16247431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
    Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation.
    Sevilla J; Rodríguez A; Hernández-Maraver D; de Bustos G; Aguado J; Ojeda E; Arrieta R; Hernández-Navarro F
    Ann Hematol; 2002 Jan; 81(1):11-5. PubMed ID: 11807629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Physiopathology and possible clinical use of hematopoietic stem cells. Recent advances].
    Testa U
    Recenti Prog Med; 2009 Mar; 100(3):144-55. PubMed ID: 19475843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
    Klaus J; Herrmann D; Breitkreutz I; Hegenbart U; Mazitschek U; Egerer G; Cremer FW; Lowenthal RM; Huesing J; Fruehauf S; Moehler T; Ho AD; Goldschmidt H
    Eur J Haematol; 2007 Jan; 78(1):21-8. PubMed ID: 17042762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cell transplantation in hematologic malignancy.
    Archuleta TD; Devetten MP; Armitage JO
    Panminerva Med; 2004 Mar; 46(1):61-74. PubMed ID: 15238882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.
    Novotny JR; Rosenthal C; Elmaagacli AH; Dürig J; Beelen DW; Dührsen U
    Eur J Haematol; 2004 Jul; 73(1):1-9. PubMed ID: 15182331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local irradiation prior to stem cell harvest has no influence on CD34+ yield: a quantitative analysis.
    Rinn JP; Schwella N; Wollmer E; Jaques G; Heinzel-Gutenbrunner M; Strassmann G; Gross MW; Movassaghi K; Neubauer A; Ritter M
    Ann Hematol; 2006 Jan; 85(1):38-44. PubMed ID: 16012838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
    Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S
    Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
    Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
    Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
    Valcárcel D; Martino R
    Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood and marrow transplantation activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT).
    Gratwohl A; Passweg J; Baldomero H; Hermans J
    Bone Marrow Transplant; 1999 Aug; 24(3):231-45. PubMed ID: 10456992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.
    Hill GR; Morris ES; Fuery M; Hutchins C; Butler J; Grigg A; Roberts A; Bradstock K; Szer J; Kennedy G; Morton J; Durrant S
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):603-7. PubMed ID: 16737933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
    J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.